文献速递头颈部肿瘤放疗消化道肿瘤放疗胸部肿瘤放疗

同步放化疗联合食管切除术治疗同时性头颈部与食管鳞癌的回顾性研究

Simultaneous concurrent chemoradiotherapy and esophagectomy for synchronous head and neck and esophageal squamous cell carcinoma: a retrospective review.
PubMed 文献 · Radiat Oncol · 2025-07-09

全部患者完成计划剂量放疗,1年和2年生存率分别为62.9%和34.4%,体能状态(PS)与ESCC临床反应是总生存的显著预测因素,不良反应可管理,无治疗相关死亡。

要点

  • 同步根治性放化疗(HNSCC 70 Gy/35次)与新辅助放化疗(ESCC 48 Gy/24次)同期进行,后续食管切除术可行且耐受良好。
  • 1年与2年生存率分别为62.9%和34.4%,PS与ESCC临床反应为总生存显著预测因素。

核心结论

  • 对同时性HNSCC与ESCC采用HNSCC根治性同步放化疗联合ESCC新辅助同步放化疗后行食管切除术的策略有效且耐受性良好。
  • PS与ESCC临床反应是该治疗策略的显著预后因素。

研究设计与样本

  • 放疗采用同时整合推量技术,4–5个剂量水平;CCRT期间每周接受铂类化疗。
  • ESCC新辅助CCRT后4–5周评估食管切除术;生存分析采用Kaplan-Meier法与Cox回归。

主要发现

  • 全部患者按计划剂量与照射野完成CCRT,耐受性良好。
  • 1年与2年生存率分别为62.9%与34.4%。
  • PS、ESCC肿瘤位置、HNSCC临床分期、HNSCC与ESCC临床反应(单独及联合)均与预后显著相关。
  • PS与ESCC临床反应是总生存的显著预测因素。

关键数值与推荐

  • HNSCC根治性同步放化疗剂量为70 Gy/35次。
  • ESCC新辅助同步放化疗剂量为48 Gy/24次,放疗后4–5周评估食管切除术。
  • 放疗计划采用同时整合推量技术,4–5个剂量水平。

临床怎么用

  • 对同时性HNSCC与ESCC可考虑同步实施HNSCC根治性CCRT与ESCC新辅助CCRT,并按计划行食管切除术。
  • 治疗决策与预后评估中应关注PS与ESCC临床反应。
  • 需监测3/4级中性粒细胞减少等血液学毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to assess the clinical outcomes and prognostic factors of patients with synchronous head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC) who underwent simultaneous concurrent chemoradiotherapy (CCRT) and esophagectomy. METHODS: Thirty-one patients who underwent simultaneous CCRT for synchronous HNSCC and ESCC were retrospectively reviewed. The treatment strategy involved simultaneous definitive CCRT at 70 Gy/35 fractions for HNSCC and neoadjuvant CCRT at 48 Gy/24 fractions for ESCC. Esophagectomy was evaluated 4-5 weeks after neoadjuvant CCRT. The radiotherapy plan utilized a simultaneously integrated boost technique at 4-5 dose levels. Patients received weekly platinum chemotherapy during CCRT. Patient characteristics, treatment responses, and survival rates were analyzed. Survival analysis was conducted using the Kaplan-Meier method and Cox regression analyses. RESULTS: All the patients completed CCRT at the planned doses and radiation fields with a good tolerance profile. The 1- and 2-year survival rates were 62.9% and 34.4%, respectively. Performance status (PS), ESCC tumor location, HNSCC clinical stage, and clinical responses of HNSCC and ESCC, both individually and combined, were significantly associated with prognosis. PS and the clinical response of ESCC were significant predictors of overall survival. Adverse effects were manageable, with up to eleven patients (35.5%) developing grade 3/4 neutropenia. No treatment-related mortality was noted. CONCLUSIONS: The treatment strategy using simultaneous definitive CCRT for HNSCC and neoadjuvant CCRT for ESCC followed by esophagectomy for synchronous HNSCC and ESCC is effective and well-tolerated. PS and clinical response of ESCC are significant prognostic factors for this treatment strategy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Huang YM, Leu YS, Lee JC, et al. Simultaneous concurrent chemoradiotherapy and esophagectomy for synchronous head and neck and esophageal squamous cell carcinoma: a retrospective review. Radiat Oncol. 2025. PMID: 40634977. doi:10.1186/s13014-025-02681-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。